Palatin Technologies, Inc. (PTN), Monday announced new pre-clinical data for PL9588, a novel melanocortin receptor agonist, for the treatment of for glaucoma, a progressive, often pressure-related disease.
The data revealed that PL9588 reduces intraocular pressure via aqueous outflow mechanism, provides retinal neuroprotection independent of Intraocular Pressure lowering, and supports dual-action.
The findings, presented at the 2025 Association for Research in Vision and Ophthalmology Annual Meeting, position PL9588 as a potential next-generation candidate for glaucoma treatment.
In the pre-market hours, Palatin's stock is trading at $0.215, down 1.33 percent on the New York Stock Exchange American.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.